Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 15,618 as of Friday, Aug. 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,354 issues advancing vs. 1,554 declining with 118 unchanged. The Health Care sector currently sits up 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Sirona Dental Systems ( SIRO), down 5.3%, Regeneron Pharmaceuticals ( REGN), down 2.3%, Vertex Pharmaceuticals ( VRTX), down 2.0%, Celgene Corporation ( CELG), down 2.0% and Baxter International ( BAX), down 1.9%. Top gainers within the sector include Biogen Idec ( BIIB), up 2.8%, Smith & Nephew ( SNN), up 2.6%, Grifols ( GRFS), up 1.3% and Pfizer ( PFE), up 0.6%. TheStreet would like to highlight 5 stocks pushing the sector lower today: 5. CareFusion ( CFN) is one of the companies pushing the Health Care sector lower today. As of noon trading, CareFusion is down $2.96 (-7.6%) to $35.99 on heavy volume. Thus far, 7.6 million shares of CareFusion exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $35.06-$39.14 after having opened the day at $39.14 as compared to the previous trading day's close of $38.95. CareFusion Corporation provides various healthcare products and services in the United States and internationally. It operates in two segments, Medical Systems and Procedural Solutions. CareFusion has a market cap of $8.5 billion and is part of the health services industry. Shares are up 35.0% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.